Johnson & Johnson
Financial Performance
Johnson & Johnson Revenue & Financials
Revenue
$94.2B (FY2025)
Market Cap
$643.9B
Net Income
$26.8B
Employees
140,800
What is Johnson & Johnson's revenue?
Johnson & Johnson had $94.2B in revenue for fiscal year 2025, up 6% from 2024. Net income was $26.8B.
- Latest revenue
- $94.2B (FY2025)
- Year-over-year
- +6%
- Growth rate (CAGR)
- 3% over 9 years
- Peak revenue
- $94.2B (FY2025)
- Years of data
- 10
- Employees
- 140,800
- How much profit does Johnson & Johnson make?
- Johnson & Johnson reported net income of $26.8B for fiscal year 2025. sec.gov
- How many employees does Johnson & Johnson have?
- Johnson & Johnson has about 140,800 employees.
Financial Analysis
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026. Johnson & Johnson is a healthcare juggernaut, maintaining a massive market valuation often exceeding $350 billion.
Revenue Trend Analysis
YoY Change
+6%
9-Year CAGR
+3%
Peak Year
2025
Trend
Consistent Growth
Johnson & Johnson has 10 full fiscal year figures on this page, compounding at +3% annually over 9 years. The most recent year saw a 6% increase versus the prior year. Annual revenue peaked in fiscal year 2025 at $94.2B. Of 9 comparable year-over-year steps, 8 showed growth and 1 showed a decline.
Annual revenue history
Click any row to see year details.
Johnson & Johnson balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 10-K, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Total liabilities | Free cash flow | Source |
|---|---|---|---|---|---|---|
| FY2025ended Dec 28, 2025 | $24.5B | $4.8B | $199.2B | $117.7B | $19.7B | Form 10-K |
| FY2024ended Dec 29, 2024 | $24.3B | $4.4B | $180.1B | $108.6B | $19.8B | Form 10-K |
| FY2023ended Dec 31, 2023 | $22.8B | $4.5B | $167.6B | $98.8B | $18.2B | Form 10-K |
| FY2022ended Jan 1, 2023 | $21.2B | $4B | $187.4B | $110.6B | $17.2B | Form 10-K |
| FY2021ended Jan 2, 2022 | $23.4B | $3.7B | $182B | $108B | $19.8B | Form 10-K |
| FY2020ended Jan 3, 2021 | $23.5B | $3.3B | $174.9B | $111.6B | $20.2B | Form 10-K |
| FY2019ended Dec 29, 2019 | $23.4B | $3.5B | $157.7B | $98.3B | $19.9B | Form 10-K |
| FY2018ended Dec 30, 2018 | $22.2B | $3.7B | $153B | $93.2B | $18.5B | Form 10-K |
| FY2017ended Dec 31, 2017 | $21.1B | $3.3B | $157.3B | $97.1B | $17.8B | Form 10-K |
| FY2016ended Jan 1, 2017 | $18.8B | $3.2B | $141.2B | $70.8B | $15.5B | Form 10-K |
Keep researching Johnson & Johnson
Johnson & Johnson Revenue and Financial FAQ
What is Johnson & Johnson's annual revenue milestone and growth baseline?
Johnson & Johnson reported sales of $94.2 billion in FY2025, up 6.0% from $88.8 billion in FY2024. In July 2026 it raised 2026 guidance to $100.8 to $101.4 billion.
How did J&J perform in Q2 2026?
Q2 2026 sales rose 6.6% to $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion). Net earnings were $5.53 billion, diluted EPS was $2.27, and adjusted EPS was $2.90.
What is J&J's dividend track record and Dividend King status?
Johnson & Johnson is a prestigious Dividend King, having increased its annual dividend payout for 64 consecutive years as of April 2026, distributing over $11.5 billion to $12 billion annually in cash dividends to shareholders.
How much does Johnson & Johnson spend on R&D?
J&J spends well over $10 billion a year on research and development, one of the largest R&D budgets in healthcare. Exact annual figures are reported in its Form 10-K.
What was the financial impact of spinning off Kenvue in 2023?
In August 2023, J&J completed the tax-free exchange offer separating Kenvue (Consumer Health: Tylenol, Band-Aid, Listerine), reducing J&J's outstanding share count by 191 million shares (generating $13.2B in cash proceeds) and accelerating J&J's overall enterprise revenue growth and profit margin profile.
How much free cash flow does J&J generate?
J&J estimated first-half 2026 free cash flow at about $8.7 billion, versus $6.2 billion a year earlier, according to its Q2 2026 release.
Where does J&J earn its revenue geographically?
The US is J&J's largest market. In Q2 2026, US sales were $14.53 billion (about 57% of total) and international sales were $10.78 billion.
How does J&J manage legacy talc litigation liabilities through structured settlements?
After a bankruptcy judge rejected the Red River Talc plan on March 31, 2025, J&J returned to the tort system. On July 27, 2026 it announced a proposed resolution of remaining ovarian talc claims estimated at about $5.5 billion, conditioned on at least 95% claimant participation.
Is Johnson & Johnson financially stable?
They are one of the most financially invincible companies on Earth. J&J is one of only two US corporations (alongside Microsoft) to hold a massive, perfect AAA credit rating (higher than the US Government). To boost profit margins even higher, they executed a massive spin-off in 2023, dumping their lower-margin consumer products (Tylenol, Listerine) into a new public company called Kenvue.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Johnson & Johnson Revenue & Financials." CorpDigest, https://corpdigest.com/company/johnson-and-johnson/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Johnson & Johnson reported $94.2B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/johnson-and-johnson/financials" target="_blank" rel="noopener">CorpDigest — Johnson & Johnson financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Johnson & Johnson
Core profile pages, founders and related research hubs for this company.